Immunoreactivity of p53, Ki‐67, and c‐<i>erbB</i>‐2 in phyllodes tumors of the breast in correlation with clinical and morphologic features

Shpitz, Baruch; Bomstein, Yonit; Sternberg, A; Klein, Ehud; Tiomkin, V.; Kaufman, Arieh Y.; Groisman, Gabriel M.; Bernheim, Joëlle

doi:10.1002/jso.10049

Cited by 47 publications

(27 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Shpitz et al has reported that the expression of p53 tends to be higher in phyllodes tumors of higher malignant potential. 46 Thus, it is possible that heparan sulfate may cooperate with p53 in regulating cell cycle progression in phyllodes stromal cells. Also, the epithelial expression of bcl2, a well-known antiapoptotic protein, is decreased in malignant phyllodes tumors with little or no 10E4 staining.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors

et al. 2006

View full text Add to dashboard Cite

Phyllodes tumors are fibroepithelial neoplasms typified by stromal proliferation. We have previously shown the role of pathologic parameters and the prognostic significance of p53 and CD117 protein expression in these tumors. In this study, we evaluated the expression of heparan sulfate, which has been implicated in many biological processes such as cell adhesion, embryogenesis, and tumorigenesis (including malignant transformation of mammary cells) in 232 breast phyllodes tumors. We used a monoclonal antibody, 10E4, to examine the localization of heparan sulfate in phyllodes tumors by immunohistochemistry. The immunoreactivity of both epithelial and stromal components was examined and analyzed with pathological parameters and other immunohistochemical markers, including p53, MIB1, bcl2, and CD117. Stromal 10E4 expression was significantly associated with tumor grade, stromal p53, and MIB1 expression in proliferating cells, suggesting that heparan sulfate may participate in malignant tumor growth.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors

et al. 2006

View full text Add to dashboard Cite

show abstract

“…In phyllodes tumors there is increased p53 protein expression in higher-grade lesions compared with lower-grade lesions [3,[18][19][20], and the staining pattern in malignant phyllodes tumors, and very occasionally in borderline tumors, is characteristically diffuse strong nuclear staining, particularly in the high cellularity area and in the sub-epithelial location [3]. p53 has been shown to be associated with atypia, tumor grade, prominent stromal overgrowth, mitotic count, stromal nuclear pleomorphism, high stromal mitotic count, and an infiltrative margin [3,19,[21][22][23]. Most studies however were unable to demonstrate the ability of p53 to predict outcome or recurrence [3,19,22], although one series suggested that increased p53 expression in phyllodes tumors correlated with worse disease or recurrence-free survival [24].…”

Section: Biological Markersmentioning

confidence: 96%

Phyllodes tumor of the breast: an update

2009

View full text Add to dashboard Cite

Phyllodes tumor is an uncommon biphasic breast tumor, with the ability to recur and metastasize, and it behaves biologically like a stromal neoplasm. Traditionally, phyllodes tumors are graded by the use of a set of histologic data into benign, borderline, and malignant. In most series, all phyllodes tumors may recur, but only the borderline and malignant phyllodes tumors metastasize. On the basis of histologic features, prediction of behavior is difficult. The expression of many biological markers, including p53, hormone receptors, proliferation markers, angiogenesis group of markers, c-kit, CD10 and epidermal growth factor receptor have been explored, and many have been shown to be variably expressed, depending on the grade of the tumor. These markers are, however, of limited value in predicting the behavior of the tumor. Recently investigators have reported a plethora of genetic changes in phyllodes tumors, the most consistent of which seems to be 1q gain by comparative genomic hybridization. Some candidate genes have been mapped to various sites, and preliminary data suggest that some of these changes may be related to recurrence. It is foreseeable that more exciting data will be generated to help us to understand the etiology and pathogenesis of phyllodes tumor.

show abstract

“…Studies have shown that p53, Ki67, CD117, 34,35 EGFR, 36 p16, 37 and VEGF 38 (being the lowest in benign PT and the highest in malignant PT) are associated with histologic grades of PT, but none has been proven to be clinically useful. Among these markers, p53 expression and Ki67 index were reported in some studies 39,40 to be significantly associated with disease-free and overall survivals, but other studies 41,42 found no association with recurrence or clinical behavior. PAX3 and SIX1 expression by immunohistochemistry 43 and gene-expression analysis 44 has recently been identified in borderline and malignant PTs and correlates with a poor clinical outcome.…”

Section: Molecular/genetic Featuresmentioning

confidence: 98%

Phyllodes Tumor of the Breast: Histopathologic Features, Differential Diagnosis, and Molecular/Genetic Updates

Zhang

Kleer

2016

Archives of Pathology &Amp; Laboratory Medicine

202

204

View full text Add to dashboard Cite

Context.-Phyllodes tumor (PT) of the breast is a rare fibroepithelial neoplasm with risks of local recurrence and uncommon metastases. The classification proposed by the World Health Organization for PTs into benign, borderline, and malignant is based on a combination of several histologic features. The differential diagnosis between PT and fibroadenoma and the histologic grading of PT remain challenging. In addition, the molecular pathogenesis of PT is largely unknown.Objective.-To provide an updated overview of pathologic features, diagnostic terminology, and molecular alterations of PT.Data Sources.-Current English literature related to PT of the breast.Conclusions.-Phyllodes tumor shows a wide spectrum of morphology. There are no clearly distinct boundaries between PT and fibroadenoma. Strict histologic assessment of a combination of histologic features with classification can help to achieve the correct diagnosis and provide useful clinical information. The genomic landscapes of PT generated from genomic sequencing provide insights into the molecular pathogenesis of PT and help to improve diagnostic accuracy and identify potential drug targets in malignant PT.

show abstract

Immunoreactivity of p53, Ki‐67, and c‐erbB‐2 in phyllodes tumors of the breast in correlation with clinical and morphologic features

Cited by 47 publications

References 25 publications

Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors

Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors

Phyllodes tumor of the breast: an update

Phyllodes Tumor of the Breast: Histopathologic Features, Differential Diagnosis, and Molecular/Genetic Updates

Contact Info

Product

Resources

About